Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.

Cite

CITATION STYLE

APA

Yamazaki, M., Sugiura, H., Iwatani, Y., Kyoda, M., Nokiba, H., Amemiya, N., … Tsuchiya, K. (2019). Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome. Case Reports in Nephrology, 2019. https://doi.org/10.1155/2019/3580941

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free